Matinas BioPharma (MTNB) Lifted to “Buy” at Zacks Investment Research
Matinas BioPharma (NYSEAMERICAN:MTNB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The brokerage currently has a $1.25 price objective on the stock. Zacks Investment Research‘s price target indicates a potential upside of 19.05% from the stock’s current price.
According to Zacks, “Matinas BioPharma is a clinical-stage biopharmaceutical company focused on enabling the delivery of life-changing medicines using its LNC platform technology. The Company’s proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic and orally bioavailable. The Company’s lead anti-fungal product candidate, MAT2203, utilizes its proprietary lipid nano-crystal formulation technology for the safe and effective delivery of the broad-spectrum fungicidal agent, amphotericin B. Based on the positive patient clinical data reported in 2017, Matinas is preparing for a potential Phase 2 pivotal trial of MAT2203 for prevention of invasive fungal infections in patients with acute lymphoblastic leukemia. “
Separately, Roth Capital assumed coverage on shares of Matinas BioPharma in a report on Monday, February 11th. They set a “buy” rating and a $4.75 price objective for the company.
Matinas BioPharma (NYSEAMERICAN:MTNB) last announced its quarterly earnings data on Tuesday, April 2nd. The company reported ($0.03) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.03).
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. D. E. Shaw & Co. Inc. purchased a new position in Matinas BioPharma during the 4th quarter valued at about $26,000. Private Advisor Group LLC increased its position in Matinas BioPharma by 100.4% during the 4th quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock valued at $30,000 after purchasing an additional 24,978 shares during the period. Virtu Financial LLC purchased a new position in Matinas BioPharma during the 4th quarter valued at about $39,000. Renaissance Technologies LLC increased its position in Matinas BioPharma by 325.6% during the 3rd quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $124,000 after purchasing an additional 103,200 shares during the period. Finally, Northern Trust Corp increased its position in Matinas BioPharma by 18.9% during the 4th quarter. Northern Trust Corp now owns 182,641 shares of the company’s stock valued at $109,000 after purchasing an additional 29,072 shares during the period.
Matinas BioPharma Company Profile
Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.
See Also: Bear Market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.